ArticleInternational urology and nephrology2025
Application of teriparatide in CKD-related osteoporosis: efficacy and safety considerations.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
The efficacy and safety of teriparatide in treating osteoporosis associated with chronic kidney disease (CKD) exhibit variability. Vetrano et al. demonstrated that teriparatide can improve bone density in renal transplant recipients with low bone turnover, with a favorable safety profile. In contrast, Hara et al. found that alendronate was more effective in preventing fractures in patients with CKD stages 3b/4. This discrepancy may be linked to CKD staging and the degree of bone metabolic disturbances. Responses in bone turnover markers are also inconsistent. In advanced CKD patients, the increase in bone resorption markers is limited. The risk of hypercalcemia (22.2%) is associated with the patient's calcium-phosphate metabolism status and parathyroid function. Future research should incorporate bone biopsy and multicenter studies to clarify the efficacy differences across CKD stages and bone turnover types, optimizing individualized application strategies.
Indexed as
Identifiers
40465117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.